Standard BioTools director buys 75,000 shares

The purchase was reported without a Rule 10b5-1 plan.

Available on EDGAR 11/05/2026 - 05:36 PM EST Accepted by SEC EDGAR 11/05/2026 - 05:36 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Standard BioTools Inc. (LAB) director Thomas D. Carey purchased 75,000 shares of common stock at $0.6253 per share on November 5, 2026. The purchase was direct; his reported holdings afterward were 419,456 shares.

Insider Trade Summary

Net Buyer: 75,000 shares

Net Buy 1 txn

Insider Carey Thomas D.

Role Director

Bought 75,000 shs ($47K)

Increase in Position 21.8%

Type	Security	Shares	Price	Value
Purchase	Common Stock	75,000	$0.6253	$47K

Holdings After Transaction: Common Stock — 419,456 shares (Direct)

Holdings Before and After: Common Stock, 344,456 to 419,456 shares (Direct)

Key Figures

Shares purchased: 75,000 shares Purchase price per share: $0.6253 per share Shares held after purchase: 419,456 shares

3 metrics

Shares purchased 75,000 shares November 5, 2026

Purchase price per share $0.6253 per share November 5, 2026

Shares held after purchase 419,456 shares Reported after the November 5, 2026 purchase

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LAB shares did director Thomas D. Carey buy?

Thomas D. Carey, a director of Standard BioTools Inc. (LAB), purchased 75,000 shares of common stock at $0.6253 per share on November 5, 2026. The purchase was direct, and his reported holdings afterward were 419,456 shares. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carey Thomas D.

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

50 MILK STREET, 10TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/05/2026		P		75,000	A	$0.6253	419,456	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Thomas D. Carey by Tomone Tanaka, Attorney-in-Fact	11/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)